Results for tag: "Dengvaxia"

Dengvaxia is a vaccine developed by Sanofi Pasteur to protect against dengue fever. It is the first vaccine approved for the prevention of dengue fever in humans. The vaccine is administered as a three-dose series over a six-month period. It is approved for use in individuals aged nine to 45 years old who live in endemic areas. The Dengvaxia market is composed of a variety of stakeholders, including vaccine manufacturers, healthcare providers, and public health organizations. Vaccine manufacturers are responsible for the development, production, and distribution of the vaccine. Healthcare providers are responsible for administering the vaccine to patients. Public health organizations are responsible for educating the public about the vaccine and its benefits. The Dengvaxia market is composed of several companies, including Sanofi Pasteur, GlaxoSmithKline, Merck, Pfizer, and Johnson & Johnson. These companies are responsible for the development, production, and distribution of the vaccine. Show Less Read more